Adenovirus type 4 a

Ended Awarded Last action

Contract number
SPE2DP26F4639
Awardee
Awarding agency
Obligated
$515,290

Award facts

Contract value 100% obligated
$515,289.60 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
325412 Pharmaceutical Preparation Manufacturing
PSC
6505 Drugs And Biologicals
Set-aside
No set-aside
Competition
Not Competed Only One Source
Pricing
Firm Fixed Price
Place of performance
Parsippany, NJ 07054, USA

Award details come from SAM.gov/FPDS.

About this award

The Department of Defense Medical Supply Chain issued a $515,289.60 delivery order to Teva Pharmaceuticals USA, Inc. on April 15, 2026, for Adenovirus Type 4 vaccine, with ultimate completion by April 29, 2026.

Place of performance is Parsippany, New Jersey. The order is firm fixed price with no set-aside designation. Teva is a large business foreign-owned subsidiary of an Israeli pharmaceutical manufacturer and a critical federal supplier of vaccines and specialty pharmaceuticals to the Department of Defense, Department of Veterans Affairs, Bureau of Prisons, and Indian Health Service.

Quick answers

Who was awarded contract SPE2DP26F4639?

SPE2DP26F4639 was awarded to Teva Pharmaceuticals Usa, Inc. by Medical Supply Chain (Troop Support) on April 15, 2026.

How much is contract SPE2DP26F4639 worth?

The government has obligated $515,290 on SPE2DP26F4639.

Is contract SPE2DP26F4639 an order under another contract?

Yes. SPE2DP26F4639 is a delivery order under SPE2DP20D0002, an indefinite delivery contract.

Was contract SPE2DP26F4639 competed?

The extent of competition for SPE2DP26F4639 was not competed.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award